PDCD1 and neoplasm: Unlike the neutralizing antibody to PD-L1 or PD-1 proteins, treatment of PD-L1xCD3 BiTE not only inhibits the PD-1/PD-L1 immune escape signaling but also enhances T cell anti-tumor activity to improve the treatment success rate.